Medications mostly associated with ejaculatory disorders: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries
Antonio Nacchia,Antonio Franco,Antonio Cicione,Sara Riolo,Giuseppe Santoro,Matteo Romagnoli,Luca Sarcinelli,Daniele Fiasconaro,Nicola Ghezzo,Giacomo Gallo,Giorgia Tema,Antonio Luigi Pastore,Yazan Al Salhi,Andrea Fuschi,Antonio Carbone,Giorgio Franco,Riccardo Lombardo,Andrea Tubaro,Cosimo De Nunzio
DOI: https://doi.org/10.1016/j.urology.2023.12.021
IF: 1.555
2024-02-09
Urology journal
Abstract:Objectives To identify which medications are mostly associated with ejaculatory disorders through a disproportionality analysis. Methods The Food and Drug Administration Adverse Event Reporting System (FDA-FAERS) and the Eudra-Vigilance (EV) database were queried to identify medications more commonly associated to ejaculatory disorders from 10th September 2012 to 1st June 2023. Proportional Reported Ratios (PRRs) were computed for all the selected drugs. Results Overall, 7404 reports of ejaculatory disorders reports were identified, and of these, 6854 cases (92,6%) were attributed to ten specific medications. On FDA-FAERS and EV databases, Paroxetine and Tamsulosin were the main responsible of delayed ejaculation (103/448 events, 23,0%) and retrograde ejaculation (366/1033 events, 35,4%), respectively. Finasteride was mostly related to painful ejaculation and ejaculation failure, with 150 events (7,8%) and 735 events (38,4%) respectively. Within the group of high-risk medications, Sildenafil presented higher risk of ejaculatory disorders than Tadalafil (PRR=5.85 (95%CI 5.09-6.78), p<0,01). Conclusions Ten drugs were recognized to display significant reporting levels of ejaculatory disorders. Among them, Finasteride and Sildenafil were responsible for the most reports in FDA-FAERS and in EV databases, respectively. Physicians should thoroughly counsel patients treated with these drugs about the risk of ejaculatory disorders. Further integration into clinical trials is needed to enhance the applicability and significance of these results.
urology & nephrology